Last edition
News about "AskBio"
AskBio Reports Safety Data from AB-1003 LGMD 2I/R9 Study
Data from first cohort of five participants suggest an acceptable safety profile for AB-1003 in participants with Limb-Girdle Muscular Dystrophy (LGMD) 2I/R9, with no dose-limiting toxicities or serious adverse events reported up to 52 weeks post-treatment.
AskBio | 13/10/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members